Merck Serono

/K I L L K I L L K I L L -- Merck Serono/

    We are advised by Merck Serono that journalists and other readers should  disregard the news release "Erbitux Significantly Prolongs Survival in  1st-Line Treatment of Non-Small Cell Lung Cancer" NYSE:SRA, issued today  due to premature release. This release will be reissued at a later date.

ots Originaltext: Merck Serono
Im Internet recherchierbar: http://www.presseportal.ch

Contact:
Contact: Dr. Raphaela Farrenkopf, Phone +49-6151-72-2274



Weitere Meldungen: Merck Serono

Das könnte Sie auch interessieren: